Forum to chew on alliance issues
14 July, 2003 by Iain ScottA special BioBusiness Forum will be held in Sydney on July 22 to go over issues raised by the recent Biotechnology Alliance signed by the premiers of NSW, Victoria and Queensland.
New “pragmatic” consulting venture
08 July, 2003 by Jeremy TorrEx-Ambri CEO Dr Joe Shaw is to set up shop in Australia with a new biotech business consulting group – the Aus-American Group Inc (AAGI) – designed to help startups navigate the Pacific Trench minefield.
Queensland govt scores top marks in bioscience
07 July, 2003 by Peter YoungVictoria trails Queensland among state governments that are energetically supporting bioscience and needs to fine-tune its Bio 21 initiative, according to one of the bioIT industry's most unusual executives, Michael Armitage.
Bio 21 initiative needs tuning: SGI executive claims
02 July, 2003 by Pete YoungVictoria trails Queensland among state governments which are energetically supporting bioscience and needs to fine-tune its Bio 21 initiative, according to one of the bioIT industry's most unusual executives, Michael Armitage.
Vita Life Sciences de-lists
02 July, 2003 by Jeremy TorrReeling under a double-whammy from an allegedly fraudulent former employee and the collapse of supplier Pan Pahramaceuticals, beleaguered nutraceutical Vita Life Sciences had delisted from the ASX.
SA Joins High-Performance Computing Fraternity
01 July, 2003 by David BraueSouth Australia’s fledgling biotechnology industry has received the first of two shots in the arm with the commissioning of Hydra, a $1.7 million system that is Australia’s third-largest supercomputer and the largest of its type.
S. Australia joins high-performance computing fraternity
27 June, 2003 by David BraueSouth Australia's fledgling biotechnology industry has received the first of two shots in the arm with the commissioning of Hydra, a $AUD1.7 million system that is Australia's third-largest supercomputer and the largest of its type.
Leading scientist to head hi-tech institute
27 June, 2003 by Staff WritersA leading scientist is to be the inaugural director of the $50 million Australian Institute of Bioengineering and Nanotechnology, Queensland Premier, Peter Beattie, announced.
Computing grid spreads number-crunching across states
27 June, 2003 by David BraueData-intensive research fields such as physics and life science will soon benefit from grid computing technology, a new method for analyzing massive amounts of data demonstrated in Australia for the first time at the recent ICCS 2003 (International Conference on Computational Science) in Melbourne.
Chemeq raises $25m
25 June, 2003 by Melissa TrudingerPerth biotechnology company Chemeq (ASX: CMQ) has raised a whopping $AUD25 million in a share placement to institutional and sophisticated investors.
Consuming passions
25 June, 2003 by Jeremy TorrThe consumables market in Australia has long been supported by the lab, mining and agricultural customer. But now, biotech is changing the landscape. Faster moving, smaller and more disposable, consumables are making the move to a technology based market. Jeremy Torr reports
NSCC collaborates with LifeCell
23 June, 2003 by Melissa TrudingerThe National Stem Cell Centre (NSCC) has recruited expatriate Australian scientist Dr Stephen Livesey to be the chief scientific officer of the Centre, Victorian Premier Steve Bracks has announced on the eve of the BIO2003 conference in Washington DC.
Queensland BioCapital Fund announces first investment
19 June, 2003 by Pete YoungQueensland Premier Peter Beattie has opened his campaign to grab a slice of the spotlight for the State during Bio2003 by announcing the first investment by Australia’s largest biotechnology fund, the $100 million Queensland BioCapital Fund.
NSW pledges $205 million for new Institute
19 June, 2003 by Jeremy TorrThe NSW government has taken the first step towards fulfilling its election pledge, with $205million on the table over the next four years as funding for the new peak cancer research organsation.
Oz biotechs beat the bulls
17 June, 2003 by Jeremy TorrLocal biotech performers have overtaken the traditional basket of stocks by 13 per cent, showing a 27 per cent leap in prices, according to a report from stockbroking firm Intersuisse.
